A bill that would mandate three paid sick days is heading to Gov. Jerry Brown’s desk for a signature after the Legislature pushed the measure through.
AB 1522 cleared the Assembly and Senate in the final hours of the legislative session that stretched into Saturday morning. There is currently no requirement for paid sick days, but supporters of the bill said that with the rise in cost of living, many Californians would be unable to afford taking a day off.
The bill received support from Brown, who lauded the decision.
“Tonight, the Legislature took historic action to help hard-working Californians,” Brown said in a statement. “This bill guarantees that millions of workers – from Eureka to San Diego – won’t lose their jobs or pay just because they get sick.”
The bill, authored by Assemblywoman Lorena Gonzalez, D-San Diego, was opposed by the California Chamber of Commerce and other business groups, who contend it will drive up business costs and reduce employment.
A moratorium on adult film production has been lifted after it was determined a performer had not tested positive for HIV.
Free Speech Coalition, the Canoga Park trade group for the adult industry, called for the moratorium on Thursday after receiving an initial report of a performer testing positive for HIV.
The work stoppage was lifted Friday after the coalition determined the result was a false positive and others who had contact with the original performer had negative test results as well.
Amgen Inc. announced Tuesday it has submitted two applications to the European Medicines Agency, one for approval to sell its evolocumab cholesterol drug and another for cancer treatment talimogene laherparepvec.
The Thousand Oaks biotech announced last week it had submitted an application to the Food and Drug Administration to sell evolocumab in the United States. The drug has been tested on about 6,800 patients in clinical studies and has shown an ability to lower LDL-C, or “bad” cholesterol from the blood.
Talimogene laherparepvec is an investigational drug designed to initiate a systemic anti-tumor immune response. If approved, it will represent the first in a class of cancer drugs known as oncolytic immunotherapies.